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Abstract 
It is an accepted paradigm that extended stress predisposes an individual to pathophysiology. 
However, the biological adaptations to minimize this risk are poorly understood. Using a 
computational model based upon realistic kinetic parameters we are able to reproduce the 
interaction of the stress hormone cortisol with its two nuclear receptors, the high affinity 
glucocorticoid receptor (GR) and the low affinity pregnane X-receptor (PXR). We 
demonstrate that regulatory signals between these two nuclear receptors are necessary to 
optimise the body’s response to stress episodes, attenuating both the magnitude and duration 
of the biological response. In addition, we predict that the activation of PXR by multiple, low 
affinity endobiotic ligands is necessary for the significant PXR-mediated transcriptional 
response observed following stress episodes.  This integration allows responses mediated 
through both the high and low affinity nuclear receptors, which we predict is an important 
strategy to minimise the risk of disease from chronic stress.    
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There is a requirement for robustness within biological systems, defined as the ability of a 
system to undertake its core function despite external challenges1. Product inhibition, feed-
forward and feed-back inhibition and stimulation, as well as repression and induction 
regulatory loops allow biological systems to approach both robustness and adaptability2. 
Biological systems are routinely exposed to external challenge, such as the stress response 
where each challenge causes a transient spike in blood cortisol, activating catecholamine 
production in the brain and glucose mobilisation in the liver, forming the classical fight or 
flight response3. It is clear that prolonged or repeated stress is associated with the 
development of pathophysiology4-6; for example, high stress police work is associated 
positively with the development of metabolic syndrome7,8. As such, it is both an important 
biological question, and challenging modelling scenario, to understand how these metabolic 
networks function efficiently, balancing both the pharmacodynamic (physiological effect of 
the challenge on the biological system) and pharmacokinetic (metabolic response to the 
challenge, leading to a return to homeostasis) responses to stress: This ensures an efficient 
fight or flight response, whilst minimising the overstimulation associated with increased 
morbidity. 
Many genes responsible for the body’s responses to chemical and environmental challenge 
are regulated by members of the nuclear receptor superfamily9. These ligand-activated 
transcription factors may be divided into receptors with high affinity ligands (Kd~nM; e.g the 
glucocorticoid receptor (GR), and those with low affinity ligands (Kd~μM; e.g. the pregnane 
X-receptor (PXR) 9,10.  
Regulatory signals have been identified between nuclear receptors, although the impact of 
these on target gene expression is at present equivocal. Examples of such regulation include 
the positive regulation of PXR by GR11; the positive regulation of PXR by PPARα12, and the 
negative autoregulation of GR, PR, AR and PXR on their own expression13-15. Indeed, the 
4 
 
nuclear receptor network in its entirety holds multiple interlinked complex regulatory 
mechanisms16,17, the quantitative importance of which is only just becoming clear. 
Using a systems biology approach we reproduce a portion of this regulatory network in silico, 
based on both literature and on de novo-generated data, and demonstrate that the model can 
reproduce the known interactions between glucocorticoids, their cognate receptors and target 
gene sets. We demonstrate the utility of feed-forward and feed-back regulatory signals in 
optimising the response to a stress challenge. Importantly, we demonstrate that the regulatory 
network only functions as a direct result of the promiscuity of the PXR ligand profile, with 
integration from multiple, low affinity endogenous chemicals being obligate for activation of 
PXR by the nanomolar concentrations of cortisol released during a stress response. Finally, as 
multiple stress exposures are a more likely scenario in the real world, we examine how the 
system responds to repeated stimuli of differing frequency. We demonstrate that the network 
is robust towards low frequency perturbations, shows adaptation at moderate stress 
frequencies, but transitions to an altered steady state at high frequency stimulation, which we 
predict is predisposing towards stress-induced pathologies.  
 
Results 
Model Generation and validation 
We generated an in silico model of the regulatory signal network known to regulate body 
responses to glucocorticoids in the human liver, allowing examination of both 
pharmacodynamic and pharmacokinetic responses to stress. Fig. 1A represents a cartoon of 
the basic network structure, while Fig. S1 provides the complete model in SBGN format and 
tables S1-S4 the model parameters, balance equations, conserved moieties and initial 
conditions used to populate the model, respectively. Within this model, cortisol (ligand ‘L’) 
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may interact with two nuclear receptors; the high affinity GR and the low affinity PXR. 
Activation of GR by ligand, forming GRL, has three effects on the network: First, a feedback 
regulatory signal causes transcriptional repression of GR13; second, a feed-forward regulatory 
signal increases PXR expression, again at the transcriptional level11; third, GRL up-regulates 
the transcription of a target gene set, including the classic marker gene tyrosine 
aminotransferase (TAT18), which we use to represent the pharmacodynamic response. 
Activation of PXR by ligand (forming PXRL) has a single action; stimulation of a second 
target gene set, including the marker gene CYP3A419. The reduction in concentration of 
ligand L by an enhanced activity of CYP3A4 is incorporated into the model, allowing us to 
simulate the dynamic response to ligand challenge, and making CYP3A4 a surrogate marker 
for the pharmacokinetic response. It should be noted that while heterologous over-expression 
experiments have shown that GR activation can have an impact on CYP3A4 reporter gene 
expression20 other in vitro experiments clearly demonstrate that any interaction must be 
indirect as there is no consensus GRE within the CYP3A4 regulatory region21, and GR ChIP-
Seq experiments fail to demonstrate a direct interaction22,23. 
The model is defined by series of balance and rate equations. Where available parameters 
were taken from the literature (table S1), with the remaining parameters fitted to the known 
biological behaviour of the system, whilst maintaining these parameters within biologically 
realistic bounds (e.g. average gene transcription rate). Using these specifications, the model 
corresponds to the most realistic possible considering the current state of knowledge.   
The model was validated by reproducing the response of primary human hepatocytes exposed 
to the glucocorticoid cortisol. Cortisol  is a high affinity GR ligand (Kd=10 nM24), and a low 
affinity PXR ligand (Kd=10 μM25). As can be seen from Fig. 1B, the model replicates the 
dose-dependent modulation of GR, PXR, CYP3A4 and TAT steady-state mRNA levels 
observed in primary human hepatocytes exposed to cortisol; moreover, the model was able to 
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qualitatively replicate the increases in CYP3A4 protein and activity levels observed in 
primary human hepatocytes (Fig. 1C). Furthermore, the model replicates the effect of the 
artificial glucocorticoid dexamethasone on primary human hepatocytes (Fig. S2).  
All the predicted changes were half complete at cortisol concentrations of approximately 10 
nM, equivalent to the Kd for its binding to GR.  This is readily understood for TAT, GR and 
PXR as they are all impacted by the level of GRL. CYP3A4 mRNA and protein 
concentrations were also half regulated at 10 nM cortisol, which is potentially 
counterintuitive as CYP3A4 expression is regulated by PXRL, and yet the Kd between 
cortisol and PXR is approximately 1000-fold higher than this. As such, the need for further 
examination of the network is clear. 
These results demonstrate that the generated in silico network was sufficiently parameterised 
to allow meaningful interrogation of the biological scenario. It should be noted that although 
these data prove the model competent to describe the variations in the indicated species 
following cortisol challenge, they do not conclusively prove the fidelity of the model for 
other properties and perturbations.  
Impact of GR-mediated feedback regulatory signal on network dynamics 
GRL invokes both a negative feedback loop on GR expression and a positive feed-forward 
regulation on PXR transcription. To examine the importance of these regulatory interactions, 
we simulated the dynamics of the network following a sustained increase of cortisol levels. 
We then determined the importance of the two regulatory interactions by disabling either the 
negative feedback loop (a network variant we shall refer to as ‘GRstubborn’), or the positive 
feed forward regulation (the ‘PXRstubborn’ variant).   
7 
 
In the wild-type network, a decrease in both the transcript and protein levels of GR were 
simulated in response to a sustained intracellular level of 10 nM cortisol, confirming the 
operation of the GR-mediated autoregulatory feedback loop (Fig. 2A).   In addition, the 
increases in both PXR transcript and protein levels were semi-transient in nature, with the 
reduction of PXR expression by GRL via the feed-forward signal providing the mechanistic 
rationale. Simulation of the same exposure on the GRstubborn network predicted no 
alteration in transcript or protein levels for GR (both GR+GRL) and  a persistent elevation in 
PXR due to the sustained higher GRL levels (Fig. 2A).  Hence, the GR-mediated negative 
feedback loop can be seen to impact upon levels of GR (directly) and PXR (indirectly). 
The GR negative feedback loop also impacts on the expression of GR and PXR target genes. 
The negative feedback loop acts to attenuate expression of the classical GR target gene TAT 
(Fig. 2B), with the GRstubborn variant resulting in a predicted temporal persistence of TAT 
expression. This negative feedback loop also produces a modest decrease in the long term 
expression of the PXR target gene CYP3A4 (Fig. 2B).  
Impact of GR-mediated feed forward regulatory signal  
We next examined the role of the GR-mediated feed forward signal, whereby GRL stimulates 
PXR gene expression. The PXRstubborn variant predicted no alteration in transcript or 
protein levels for PXR, or TAT and GR in response to 10nM intracellular cortisol, the latter 
being understandable as their regulation is controlled upstream of this regulatory loop within 
the netw (Fig. 2A).  For the PXRstubborn variant, the increase in CYP3A4 levels following 
10nM intracellular cortisol was less than simulated in the complete model, but the change in 
AUC was modest (~15%: Fig. 2B).  
The molecular rationale behind this apparent lack of control becomes clear if the relative 
affinities of cortisol towards PXR and GR are considered: The Kd of cortisol for PXR is 
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approximately 1000-fold higher than the Kd for GR. A biologically realistic maximal 
intracellular concentration for cortisol is 10nM, as used in this simulation, and results in 50% 
occupancy of GR (Kd≈10nM), but only 0.1% occupancy for PXR (Kd≈10μM). Under the 
simulated exposure paradigm, total PXR protein level is predicted to increase by 17nM due to 
the GRL-mediated feed-forward regulatory signal. However, this results in an increase of 
PXRL of less than 0.02nM, producing a very small impact on PXR target gene expression. 
Given that these conditions are biologically realistic with respect to receptor and ligand 
concentrations, plus the affinity of cortisol for both GR and PXR, we are left with a paradox; 
why does a feed forward regulatory signal exist that appears poorly-functional under normal 
biological conditions?   
To answer this apparent paradox, we further considered the basic biology of PXR. Although 
originally described as a promiscuous nuclear receptor with many endogenous and xenobiotic 
ligands26-28, PXR has largely become thought of as a xenosensor29,30. Recent work has 
refocused on the role of PXR in endogenous processes15,31,32, and we would suggest that the 
known feed forward regulation of PXR expression by endosensing steroid hormone receptors 
such as the GR, ER and PPAR11,14 would be supportive of such a role. At any given time the 
intracellular milieu will contain a number of low affinity endogenous PXR ligands, and we 
must, therefore, consider not only the role of individual endobiotic ligands, but also their 
collective effect. Each of these ligands (L1…Ln) individually is present in the cell at a low 
concentration (nM), and coupled with low affinities (Kd≈μM) occupancy of PXR by any one 
ligand (PXRL1...PXRLn) would be negligible. However, if the levels of these endogenous 
ligands are integrated, then it should be possible to achieve a total ligand pool that will result 
in a significant level of PXR occupancy. This would result in higher level of activated PXR 
under baseline conditions, and hence PXR target genes such as CYP3A4. Importantly, the 
GR-mediated feed forward regulatory signal means that cortisol challenge now has an 
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unexpected effect; increased PXR leads to not only an increase in PXRL (e.g. PXR activated 
by cortisol) but also PXRL2..PXRLn (e.g PXR activated by all other endogenous ligands, 
hereafter referred to as ligand pool L2).  
To examine this scenario we introduced a second ligand pool (L2), representing the 
integration of all endogenous ligands for PXR present within the cell. This pool was set to a 
concentration of 100nM, with a Kd = 10μM, which we believe is not inconsistent with a 
biologically realistic value. The model parameters, balance equations, conserved moieties and 
initial conditions used to populate this model are presented in tables S5-S8, respectively. 
Following addition of the second ligand pool, the impact of cortisol challenge to a sustained 
intracellular level of 10nM on the network was simulated for the wild type, GRstubborn and 
PXRstubborn networks (Fig. 3). As predicted, the presence of the L2 ligand pool had little 
impact upon the dynamic response of PXR, GR or TAT. For CYP3A4, however, two notable 
effects were predicted: First, the transcript and protein levels were significantly higher under 
the steady-state baseline prior to cortisol addition (1628nM versus 111nM for L1+L2 and L1 
alone, respectively). Second, the GR-mediated feed forward regulatory signal is now fully 
functional, being responsible for approximately 80% of the increase in CYP3A4 AUC 
observed upon cortisol challenge. This strong dependence on the feed forward regulation is 
understandable as added cortisol has a dual effect on CYP3A4 expression; the first is rapid 
and due to binding of L to pre-existing PXR.  The second is slower and is due to binding of L 
and L2 to PXR that is produced de novo through the action of the GRL-mediated feed 
forward regulatory signal. Together, these effects increase the total activated PXR pool 
(PXRL+PXRL2) by over 10-fold compared to PXRL alone.   
An intriguing extension of this prediction is that L2 ligand pool size actually drives target 
gene induction, with larger L2 pools producing significantly more activated PXR 
(PXRL+PXRL2) due to the GR-mediated feed-forward regulatory signal. Fig. S3 
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demonstrates that as L2 pool size increases, so does the predicted basal expression of 
CYP3A4, whilst the degree to which it can be further induced decreases. This inverse 
correlation is supported by literature data, where fold induction of metabolic enzymes in 
primary human hepatocytes was observed to be inversely correlated with their basal 
expression level for a range of inducers33. 
Dynamics of the network following multiple stress episodes 
All previous simulations were undertaken using a fixed intracellular concentration of 10nM 
cortisol, consistent with our experimental model system.  However, a more clinically-relevant 
scenario involves an acute spike of cortisol released into the bloodstream following a stress 
episode. Moreover, in modern society many individuals are exposed to a number of stress 
events sequentially. We thus used the complete model to ask how the gene regulatory 
network responds to repeat blood cortisol spikes, equivalent to sequential stress episodes.  
Three different frequencies of stress episodes were examined; 1/week, 1/day or 1/hour, 
corresponding to ‘low-’, ‘medium-’ and ‘high-’ stress scenarios. Simulated protein levels for 
each of these scenarios are presented in Fig. 4, with transcript level simulations as 
supplementary data (Fig. S4). In the low-stress scenario all species were predicted to return to 
baseline following each stress episode, making each stress response independent. In contrast, 
the medium stress scenario produces new mean expression levels for all species, with protein 
levels oscillating around this new mean. For TAT, this mean approximates the maximal level 
of TAT expression seen during the low stress scenario; in contrast, GR, PXR and CYP3A4 
variances are greater. These data are consistent with an adaptive response, where the network 
has moved to a new steady-state that acts to limit the magnitude of the pharmacodynamic 
response, as measured by TAT expression. It is of particular note that while there is a 
substantial increase in blood cortisol between low and moderate frequency scenarios (AUC= 
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5-fold increase and Cmax=2.9-fold increase), the increase in TAT levels is significantly less 
(AUC=3.6-fold increase and Cmax=1.6-fold increase): This is consistent with a successful 
adaptation to medium frequency stress. However, high stress conditions predict large 
variances in all species in the model, suggesting a failure to adapt. We suggest that the 
resultant permanent increase in pharmacodynamic response, as measured by TAT expression, 
represents over-stimulation and a predisposition to increased morbidity. It is also important to 
note that alteration in non-GR target genes may be important in modulating morbidity. For 
example, expression levels of the PXR target gene CYP3A4, are predicted to increase 
dramatically in the high stress scenario (AUC=12.8-fold increase and Cmax=9.2-fold 
increase), and as CYP3A4 is responsible for the metabolism of a large number of endogenous 
steroids19,30 this may impact upon the homeostasis of these steroids, also contributing to 
increased morbidity. Despite this failure to adapt, the network can still minimise the impact 
of high stress to some degree; a dramatic increase in blood cortisol levels compared to the 
low stress scenario is observed (AUC=89-fold increase and Cmax=31.4-fold increase), but 
the increase in TAT expression levels is significantly muted (AUC=7-fold increase and 
Cmax=2.4-fold increase). 
Finally, we simulated the TAT and blood cortisol levels under conditions of moderate 
frequency stress episodes, for both the wild type network and a variant where both GR-
mediated regulatory signals had been disabled (GR/PXR Stubborn variant). The regulatory 
signals have no impact on the blood cortisol level, but the level of TAT was significantly 
impacted by the GR/PXR stubborn variant, with 1.3-fold increases in both AUC and Cmax 
compared to the wild type network simulated (Fig. 4). From this we can conclude that the 
main action of the regulatory signals is to minimise the pharmacodynamic response to 
repeated stress episodes, effectively de-sensitising the body to chronic stress.  
Adaptation to chronic stress is re-enforced through low stress periods  
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One of the design features of the network simulated herein is the ability to adapt to moderate 
levels of stress. Given that workdays are, generally, more stressful than non-workdays, we 
asked if a weekend break was beneficial for our ability to respond to moderate stress, and if 
an extended vacation was even better.  
Fig. 5 shows the simulated protein levels of all species following once per day stress events 
under three scenarios: continuous stress every day for 21 days; a weekend scenario with 5 
days of stress, followed by 2 days with no stress, for 21 days; a vacation scenario with 5 days 
of stress, followed by 9 days with no stress, and then 5 days of stress. Transcript levels are 
presented in Fig. S5. In the weekend scenario, predicted levels mirrored the 21-day constant 
stress scenario for the first 5 days, as expected. Protein levels for all species were predicted to 
return towards baseline during the low stress weekend, but did not fully recover. TAT protein 
levels were predicted to reach 82% of their baseline value, whilst PXR and CYP3A4 reached 
75% and 77%, respectively. In contrast, GR protein levels were predicted to only reach 45% 
of their baseline value. The net effect of this is a ‘biological memory’ within the network to 
the first stress episode. However, the impact of this biological memory is, perhaps 
surprisingly, minimal, with the response to stress on day 8 being only negligibly smaller than 
on day 1. However, during a 9-day vacation there appears to a significant memory effect, 
with the response to stress on the first day back from vacation being significantly less that the 
response seen on day 1. 
 
Discussion 
The glucocorticoid class of steroid hormones undertake a large number of functions central to 
normophysiology; additionally, they respond to external stress challenge, producing the ‘fight 
or flight’ response34. Much recent interest has focussed on the association between chronic 
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stress and predisposition towards disease states, including a number of complex pathologies 
such as metabolic syndrome4,35, hippocampal vulnerability6, depression36, and drug–induced 
liver injury37.  Using a systems modelling approach we have examined the regulatory signal 
network that underlies the cortisol-driven stress response under both normophysiology and 
following stress episodes. 
The signal regulatory network is centred around the interaction of the stress hormone cortisol 
with two nuclear receptors; a high affinity ligand with GR, and low affinity ligand with PXR 
(~1000-fold difference in Kd ). Glucocorticoids have previously been shown to activate feed-
back and feed-forward regulatory signals on GR and PXR expression, respectively11,13, which 
we demonstrate are important in regulating the network response as a whole. As such, we 
describe an important emergent feature of the network; the buffering of TAT levels relative to 
cortisol level following repeat stress episodes, consistent with an adaptation to minimise the 
physiological response and reducthe risk of disease progression. Such data is consistent with 
the clinical observation of Kirschbaum and colleagues, who examined the response of healthy 
men to daily stress events38. In these individuals they observed that subsequent stress events 
causing a reduced response. Even under the high stress scenario, a large degree of buffering 
occurs; however, given the available human data we would suggest that this is insufficient to 
prevent a marked increase in morbidity. For example, the chronic stress associated with 
combat scenarios has been associated with generalised disease phenotypes, such as post-
traumatic stress disorder39.   
In general, workdays are more stressful compared to weekends, yet our simulations predict 
that there is negligible difference between a stress response on day 1 of the medium stress 
scenario, and on day 8, following a weekend of no stress. In contrast, following a short 
vacation, we predict a muted response compared to the day 1 (naïve) response. A potential 
explanation for this is the differential kinetics of cortisol and the GR: Cortisol is degraded 
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relatively quickly as CYP3A4 levels are high at the start of the vacation and remain so until 
the cortisol level drops sufficiently for the GRL-mediated feed-forward regulatory signal to 
become inactive and for PXR protein to then degrade. In contrast, GR levels are influenced 
by the level of GRL, which is auto-inhibitory on GR transcription. As such, the increase in 
GR expression level following cessation of the stress episodes is predicted to lag behind the 
decrease in cortisol levels as it is dependent upon both the initial loss of cortisol to terminate 
the GRL-mediated auto-inhibitory signal, and the need to transcribe and translate GR de 
novo. Whilst the impact of this differential kinetics cannot be seen following a short weekend 
break, over a 9-day vacation there is sufficient time for a positive memory to emerge, 
effectively desensitising the network to further stress episodes.  
It should be noted that the model presented represents only a single portion of the entire 
biological system. We cannot exclude the possibility of compensatory changes to other 
proteins outside the modelled network. It would be expected that, for example, an increase in 
CYP3A4 levels would increase metabolism of its many endogenous substrates, initiating feed 
forward regulatory signals to increase steroid synthesis and return to homeostasis. Indeed, 
one potential reason for the evolution of such a regulatory signal network may be energy 
conservation, whereby a tight regulation of degradative processes is necessary to prevent 
futile energy expenditure through unnecessary anabolic processes. 
In addition, we provide a solution to the paradox that endogenous chemicals are often ligands 
for both low affinity and high affinity receptors. As intracellular levels of these steroid 
hormones are generally several orders of magnitude lower than their Kd for low affinity 
receptors, this suggests the level of PXRL will always remain low, and effectively 
biologically silent. Building on the knowledge that PXR is a promiscuous receptor with 
multiple endogenous ligands26-28 we demonstrate that integration of these individual ligands 
(PXRL1…PXRLn) results in a significant increase of PXRL, increasing transcriptional 
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activation of PXR target genes at baseline. Furthermore, through the use of the feed-forward 
regulatory loop, whereby GRL increases PXR protein levels, a single ligand (e.g. cortisol) 
can have a biologically important impact on activated PXR, impacting upon both its own 
occupation of PXR (PXRL) and other PXR ligands (PXRL2…Ln; PXRL2).  
In summary, we present a systems modelling approach to understand the design principles 
underlying the biological response to stress. We demonstrate that this network is able to 
regulate both the magnitude and duration of the physiological response to a stress episode, 
which we believe is an important design feature to protect against increased morbidity due to 
chronic overstimulation. In addition, we demonstrate that this system is robust against 
repeated stress episodes, producing only small variations in the physiological response for 
large increases of blood free-cortisol. Finally, we suggest that the differential kinetics of 
species within the network mean that a sustained vacation leads to a ‘biological memory’, 
lessening the response to subsequent stress episodes. 
 
Materials and Methods 
Primary cell Culture 
Primary human hepatocytes were a kind gift of GlaxoSmithKline, and were seeded at 2.4 x 
105 cells/cm2 in 25 cm2 flasks and allowed to attach overnight. Cells were dosed daily with 
vehicle, cortisol or dexamethsone (Sigma Aldrich, Poole, UK) at the indicated 
concentrations. Following 48 hours of exposure, total RNA and protein was isolated from 
quadruplicate samples. Total RNA was isolated using the RNeasy Mini kit (Qiagen, Crawley, 
UK) and quantified using a Nanodrop Agilent 2100 Bioanalyser, while total protein was 
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extracted in RIPA buffer (1xPBS, 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1 % SDS, 
protease inhibitor cocktail). 
Transcript level measurement 
Primers and TAMRA/FAM dual labelled probe specific for PXR, GR, CYP3A4 and 18S 
were designed using the Primer Express software (Applied Biosystems, Warrington, UK) and 
were purchased from Eurofins Wolverhampton, UK). Total RNA was treated with RNase-
free DNase (Promega, Southampton, UK) to remove genomic contamination. Reverse 
transcription was primed with random hexamers and carried out by Superscript II 
(Invitrogen) as per the manufacturer’s instructions. To ensure that DNase treated samples 
were free from genomic contamination an RT- control (lacking enzyme) was carried out for 
every RNA sample. cDNA generated from 50 ng (PXR, GR, TAT and CYP3A4) or 50 pg 
(18S rRNA) of total RNA was amplified using TaqMan Universal PCR Master Mix with 400 
nM primers and 200 nM fluorogenic probe in a total reaction volume of 25 µl. Quantitative 
polymerase chain reaction (Q-PCR) reactions were run on the ABI7000 SDS instrument and 
quantified out using the ABI proprietary software against a standard curve generated from 
human genomic DNA (Promega). 
Protein level measurement 
Total protein extracts (10 μg per lane) were resolved on 12 % SDS-polyacrylamide gels and 
then transferred electrophoretically to Hybond ECL nitrocellulose membranes (Amersham 
Biosciences, Little Chalfont, Bucks, UK).  Membranes were blocked (1 hour) in 5 % fat free 
dried milk and then probed with primary antibodies against human PXR (SAB2101636, 
1:350; Sigma-Aldrich) or α-actin (sc1616, 1:500; Autogen Bioclear), followed by anti-rabbit 
IgG (sc2030, 1:10000; Autogen Bioclear) or anti-goat IgG (sc 2020, 1:20000; Autogen 
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Bioclear) respectively.  Bound antibodies were visualised using enhanced chemiluminescence 
reagents according to the manufactures instructions (Amersham Biosciences). 
CYP3A4 protein activity measurement 
CYP3A4 enzyme activity was determined using the P450-Glo activity system (Promega, 
Southampton, UK), as per the manufacturer’s instructions. Briefly, Luciferin-PPXE substrate 
was mixed with S9 protein extract from primary human hepatocytes, along with an NADPH 
regeneration system and detection reagent. Following 20mins incubation, luminescence was 
quantified using a Packard Lumicount.  
In silico modelling 
In silico models were generated using CellDesigner (v4.0.1; Systems Biology Institute, 
http://celldesigner.org/index.html), a graphical front-end for creating process diagrams of 
biochemical networks in systems Biology Markup Language (SBML;[28]). Each individual 
chemical or protein is identified as a species (s1.....sn), while interactions between species are 
identified as reactions (r1....rn). For each reaction, a kinetic term can be included, detailing 
the mathematics underlying the interaction between the species. For more complex analysis, 
CellDesigner-generated models were transferred to COPASI (v4.6, build 32)40, which is 
another SBML-compliant programme, but with a wider variety of analysis options. 
A number of the parameter values used within the model were fitted to the known biological 
behaviour of the system, whilst maintaining these parameters within previously determined 
biologically realistic bounds. To examine the robustness of the conclusions drawn within this 
paper we undertook a sensitivity analysis for these eight parameters. As detailed in tables S9 
and S10, our conclusions were mostly robust for up to a ten-fold change in any individual 
parameter value. The only exception was the expression level of CYP3A4 within Fig. 3, as 
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affected by the rate of GRL-dependent PXR transcription; Kd of PXRL to CYP3A4 gene; 
and the rate of PXRL-dependent CYP3A4 transcription. Given that sensitivity is only 
observed for Fig. 3, where a second ligand pool is included, and not in Fig. 2, where the L2 
pool is absent, it is logical to conclude that the L2 pool is, at least in part, responsible for the 
observation. We conclude that the increased basal expression of CYP3A4 due to the L2 pool 
may decrease the robustness of the system to fluctuations in these parameters. Importantly, 
despite this altered behaviour, decreased levels of CYP3A4 are more pronounced in the PXR 
stubborn variant, which is consistent with the central conclusions of this paper. 
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Figure Legends 
Figure 1: Regulatory signal network under study and model validation: (A) A single 
ligand (L) acts as an agonist for both PXR and GR, forming an activated complex (hashed 
outline). Activated GR controls both the expression of target genes involved in the 
pharmacodynamic effect cortisol (e.g. the expression of TAT) of its ligand L (often cortisol) 
and PXR expression. Activated PXR controls the expression of target gene involved in the 
pharmacokinetic response (e.g.  CYP3A4), which acts to remove the stimulating ligand (L). 
(B) Primary human hepatocytes were exposed to vehicle or (0.1-50000 nM) cortisol as 
indicated for 48 hours, RNA extracted and transcript levels of PXR, GR, CYP3A4 and TAT 
quantified by TaqMan Q-PCR. Average transcript levels (±SEM) from triplicate cultures are 
indicated by open symbols, and the concentration-response curve shown by the full line was 
fitted to these data. Transcript levels of PXR, GR, CYP3A4 and TAT following 48 hours 
exposure to indicated concentrations of cortisol were also simulated by the model, and are 
presented as closed symbols. (C) Primary human hepatocytes were as above and total protein 
extracted. CYP3A4 protein and activity levels were measured, with the average (±SEM) from 
triplicate cultures indicated by open symbols, with concentration-response curve again fitted 
to the experimental data. Simulations of CYP3A4 protein and activity levels are presented as 
closed symbols. 
Figure 2: GR-mediated negative feedback on GR expression: Transcript and protein 
levels for (A) GR and PXR, and (B) CYP3A4 and TAT, were simulated over 3000 minutes 
following addition (in silico) of cortisol to a constant level of 10 nM. Solid lines represent 
levels simulated for the complete single-ligand model, whereas dashed lines represent levels 
GRstubborn and PXRstubborn scenarios as indicated.  
25 
 
Figure 3: Integration of endogenous ligand concentrations by PXR: Transcript and 
protein levels for (A) GR and PXR, and (B) CYP3A4 and TAT, were simulated over 3000 
minutes following addition (in silico) of cortisol to a constant level of 10 nM. In all 
simulations, an additional PXR ligand pool (L2) of concentrations equal to 100nM was 
present. Solid lines represent levels simulated for the complete single-ligand model, whereas 
dashed lines represent levels GRstubborn and PXRstubborn scenarios as indicated.  
Figure 4: Response of the gene regulatory network to repeat stress episodes: (A) Protein 
levels for GR, PXR, CYP3A4 and TAT, as well as free blood cortisol, were simulated over 
21 days following addition of repeat spikes of cortisol, such that each spike doubled the free 
blood cortisol concentration. Frequency of cortisol spikes were 1/week (grey line), 1/day 
(black line) or 1/hour (dashed line). (B) TAT and free blood cortisol were simulated as above, 
but under wild-type  (black line) and GR/PXR stubborn (grey line) network variants. 
Figure 5: A low stress vacation is required to allow adaptation to a stressful week: 
Protein levels for GR, PXR, CYP3A4 and TAT, as well as free blood cortisol, were simulated 
over 21 days following addition of repeat spikes of cortisol, such that each spike doubled the 
free blood cortisol concentration. Cortisol spikes were applied 1/day for either continuous 
throughout the period (grey line), with a weekend break (black line) or a 9-day vacation 
(dashed line).  
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Supplementary Figure S1: GR-PXR signal regulatory network: GR-PXR signal regulatory
network was constructed in using CellDesigner (v4.0.1; Systems Biology Institute,
http://celldesigner.org/index.html), a graphical front-end for creating process diagrams of
biochemical networks in Systems Biology Markup Language (SBML) and utilising Systems
Biology Graphical Notation (SBGN). Each individual chemical or protein is identified as a
species ( = gene; = mRNA; or = protein; = chemical). Interactions
between species are identified as reactions (re1....ren) , and correspond to reaction identifiers
(v1…vn) in Supplementary table S1.
Supplementary Figure S2: In silico model for the response to the artificial glucocorticoid
Dexamethasone: Primary human hepatocytes were exposed to vehicle or (0.1-50000 nM)
dexamethasone as indicated for 48 hours, RNA extracted and transcript levels of PXR, GR,
CYP3A4 and TAT quantified by TaqMan Q-PCR. Average transcript levels (±SEM) from
triplicate cultures are indicated by open symbols, and the concentration-response curve shown
by the full line was fitted to these data. Transcript levels of PXR, GR, CYP3A4 and TAT
following 48 hours exposure to indicated concentrations of cortisol were also simulated by the
model, and are presented as closed symbols.
Supplementary Figure S3: Impact of L2 pool size on response of the gene regulatory
network to an acute stress episode: Protein levels for GR, PXR, CYP3A4 and TAT were
simulated over 3000 minutes following addition of a single spike of cortisol, doubling free
cortisol concentration from 15-30nM. Simulations were undertaken in the presence of a second
PXR ligand pool (L2), at the indicated concentration. Solid lines represent levels under the
complete single-ligand model, whereas dashed lines represent levels GRstubborn and
PXRstubborn scenarios as indicated.
CYP3A4 + TAT PXR + GR
15nM
100nM
1000nM
0nM
L2 Pool Size
Supplementary Figure S4: Response of the gene regulatory network to repeat stress
episodes: Transcript levels for GR, PXR, CYP3A4 and TAT were simulated over 21 days
following addition of repeat spikes of cortisol, such that each spike doubled the free blood
cortisol concentration. Frequency of cortisol spikes were 1/week (grey line), 1/day (black line)
or 1/hour (dashed line).
Supplementary Figure S5: A low stress vacation required to allow adaptation to a stressful
week: Transcript levels for GR, PXR, CYP3A4 and TAT, as well as free blood cortisol, were
simulated over 21 days following addition of repeat spikes of cortisol, such that each spike
doubled the free blood cortisol concentration. Cortisol spikes were applied 1/day for either
continuous throughout the period (grey line), with a weekend break (black line) or a 9-day
vacation (dashed line).
Supplementary Table S1: Model Parameters for cortisol (L1) model  
Reactions Parameters 
v1 CYPmRNA synthesis:  
)(1 tCYPgenek   [nM/min] 
* 1k = 0.00321 min
-1 
v2 CYPmRNA degradation:  
)(2 tCYPmRNAk   [nM/min] 
2k = 0.04 min
-1  
41,42 
v3 CYPprotein synthesis:  
)(3 tCYPmRNAk   [nM/min] 
3k = 2.5 min
-1 41 
v4 CYPprotein degradation:  
)(4 tCYPptoteink   [nM/min] 
4k = 0.0005 min
-1
43,44 
v5 PXRmRNA synthesis on inactive PXRgene:  
)(5 tPXRgenek   [nM/min] 
* 5k = 5.52e-05 min
-
1 
v6 PXRmRNA degradation:  
)(6 tPXRmRNAk   [nM/min] 
** 6k = 0.006 min
-1 
45 
v7 PXRprotein synthesis:  
)(7 tPXRmRNAk   [nM/min] 
7k = 10 min
-1 46 
v8 PXRprotein degradation:  
)(8 tPXRptoteink   [nM/min] 
8k = 0.003 min
-1 47 
v9 GRmRNA synthesis on inactive GRgene:  
)(9 tGRgenek   [nM/min] 
* 9k  = 3.2e-06 min
-1 
v10 GRmRNA degradation:  
)(10 tGRmRNAk   [nM/min] 
** 10k  = 0.003 min
-1
45 
v11 GRprotein synthesis:  
)(11 tGRmRNAk   [nM/min] 
11k = 19.98 min
-1 48 
v12 GRprotein degradation:  
)(12 tGRptoteink   [nM/min] 
12k  = 0.001 min
-1 
48,49 
v13 TATmRNA synthesis on inactive TATgene:  
)(13 tTATgenek   [nM/min] 
* 13k  = 0.000855 
min-1 
v14 TATmRNA degradation:  
)(14 tTATmRNAk   [nM/min] 
14k  = 0.064 min
-1 50 
v15 Cortisol binding GRprotein: 
)()( 1515 tortGRproteinCkGRproteintCortk bf   [nM/min] 
fk15  = 60 nM
-1min-1 
(diffusion limited); 
bk15  = 600 min
-1 
(Kd = 10 nM 51) 
v16 GRproteinCort degradation:  
)(16 tortGRptoteinCk   [nmoles/min] 
16k  = 0.001 min
-1
48,49 
v17 Cortisol binding PXRprotein: 
)()( 1717 tCortPXRproteinkPXRproteintCortk bf   [nM/min] 
fk17  = 60 nM
-1min-1 
(diffusion limited);  
bk17  = 600000 min
-1 
52  
v18 PXRproteinCort degradation:  
)(18 tCortPXRptoteink   [nM/min] 
18k  = 0.0015 min
-1
47 
v19 Cort degradation:  
2
)(2)(1
)(
MLMC
MC
mC
K
tL
K
tCort
K
tCortV
CYPptotein


  [nM/min] 
mCV  = 10 min
-1
(kcat= mCV / 1200(nM 
max CYP protein 
conc in cell) nM = 
0.083);  
MCK =15000 nM 
Since L2=0, 
Competition 
between cortisol 
and L2 for CYP is 
neglected 53,54 
v20 PXRpoteinCortisol binding CYPgene: 
)()(20 tCYPgenetCortPXRproteink f   
)(20 teCortCYPgenPXRproteink b   [nM/min] 
fk20  = 60 nM
-1min-1 
(diffusion limited);   
* bk20  = 1 min
-1  
v21 CYPmRNA synthesis on active PXRproteinCortCYPgene:  
)(21 teCortCYPgenPXRproteink   [nM/min] 
* bk21 = 0.05 min
-1 
v22 GRpoteinCortisol binding PXRgene: 
)()(22 tPXRgenetortGRproteinCk f   
)(22 tortPXRgeneGRproteinCk b   [nM/min] 
fk22  = 60 nM
-1min-1 
(diffusion limited);   
* bk22  = 200 min
-1 
v23 PXRmRNA synthesis on active GRproteinCortPXRgene:  
)(23 tortPXRgeneGRproteinCk   [nM/min] 
* 23k = 0.00011 min
-
1 
v24 GRpoteinCortisol binding GRgene: 
)()(24 tGRgenetortGRproteinCk f   
)(24 tortGRgeneGRproteinCk b   [nM/min] 
fk24  = 60 nM
-1min-1 
(diffusion limited);   
* bk24  = 60 min
-1 
v25 GRmRNA synthesis on active GRproteinCortGRgene:  
)(25 tortGRgeneGRproteinCk   [nM/min] 
* 25k = 1.2e-06 min
-1
v26 GRpoteinCortisol binding TATgene: 
)()(26 tTATgenetortGRproteinCk f   
)(26 tortTATgeneGRproteinCk b   [nM/min] 
fk26  = 60 nM
-1min-1 
(diffusion limited);   
* bk26  = 300 min
-1 
v27 TATmRNA synthesis on active GRproteinCortTATgene:  
)(27 tortTATgeneGRproteinCk   [nM/min] 
* 27k = 0.005 min
-1  
v28 DEX binding GRprotein: 
)()( 2828 tEXGRproteinDkGRproteintDEXk bf   [nM/min] 
fk28  = 60 nM
-1min-1 
(diffusion limited);  
bk28  = 60 min
-1  
(calculated from Kd 
that is in the order 
of magnitude of 1 
nM 55) 
v29 GRproteinDEX degradation:  
)(29 tEXGRptoteinDk   [nmoles/min] 
29k  = 0.001 min
-1 
48,49 
v30 DEX binding PXRprotein: 
)()( 3030 tDEXPXRproteinkPXRproteintDEXk bf   [nM/min] 
fk30  = 60 nM
-1min-1 
(diffusion limited);;  
bk30  = 60000 min
-1 
(calculated from Kd 
that is in the order 
of magnitude of 
1000 nM 56) 
v31 PXRproteinDEX degradation:  
)(31 tDEXPXRptoteink   [nmoles/min] 
** 31k  = 0.0015 
min-147 
v32 DEX degradation:  
2:
)(2)()(1
)(
MMCMDEX
MDEX
mDEX
K
tL
K
tCort
K
tDEX
K
tDEXV
CYPptotein


  [nM/min] 
mDEXV  = 5.1 min
-1; 
((kcat= mCV / 1200 
(max CYP protein 
conc in cell) nM = 
0.00425);) 
MDEXK =23000 nM 
57  
v33 PXRpoteinDEX binding CYPgene: 
)()(33 tCYPgenetDEXPXRproteink f   
)(33 tDEXCYPgenePXRproteink b   [nM/min] 
fk33  = 60 nM
-1min-1 
(diffusion limited);   
* bk33  = 1 min
-1 
v34 CYPmRNA synthesis on active PXRproteinDEXCYPgene:  
)(34 tDEXCYPgenePXRproteink   [nM/min] 
* 34k = 0.05 min
-1 
v35 GRpoteinDEX binding PXRgene: fk35  = 60 nM
-1min-1 
)()(35 tPXRgenetEXGRproteinDk f   
)(35 tEXPXRgeneGRproteinDk b   [nM/min] 
(diffusion limited);   
* bk35  = 200 min
-1 
v36 PXRmRNA synthesis on active GRproteinDEXPXRgene:  
)(36 tEXPXRgeneGRproteinDk   [nM/min] 
* 36k = 0.00011 min
-
1 
v37 GRpoteinDEX binding GRgene: 
)()(37 tGRgenetEXGRproteinDk f   
)(37 tEXGRgeneGRproteinDk b   [nM/min] 
fk37  = 60 nM
-1min-1 
(diffusion limited);   
* bk37  = 60 min
-1 
v38 GRmRNA synthesis on active GRproteinDEXGRgene:  
)(38 tEXGRgeneGRproteinDk   [nM/min] 
* 38k = 1.2e-06 min
-
1 
v39 GRpoteinDEX binding TATgene: 
)()(39 tTATgenetEXGRproteinDk f   
)(39 tEXTATgeneGRproteinDk b   [nM/min] 
fk39  = 60 nM
-1min-1 
(diffusion limited);   
* bk39  = 300 min
-1 
v40 TATmRNA synthesis on active GRproteinDEXTATgene:  
)(40 tEXTATgeneGRproteinDk   [nM/min] 
* 40k = 0.005 min
-1 
v41 DEX transport through cellular membrane: 
)(41 tDEXoutk f   )(41 tDEXink b   [nM/min] 
fk41  = 100 min
-1;  
bk41  = 100 min
-1  
(taken at high value 
not to limit DEX 
uptake)  
v42 Endogenous cortisol synthesis: 
)(42 tCortisonek f   )(42 tCortk b   [nM/min] 
fk42  = 0.016 min
-1;  
bk42  = 0.016  min
-1 
(fitted to have 
realistic cortisol 
concentration) 
V43 TATprotein synthesis:  
)(43 tTATmRNAk   [nM/min] 
* 43k = 0.5 min
-1 
v44 
 
 
TATprotein degradation:  
)(44 tTATptoteink   [nM/min] 
44k = 0.012 min
-1 50 
VcortisolT
ransport 
Transport of cortisol through cellular membrane: 
)(tCortOUTkctf   )(tCortkctb   [nM/min] 
ctfk  = 1000 min
-1;  
ctbk  = 1000 min
-1  
VL2_PXR
_binding 
Ligand2 binding PXRprotein: 
)(2)(2 22 tLigandPXRproteinkPXRproteintLk pxrblpxrfl   
[nM/min] 
pxrfk12  = 0 nM
-1min-
1 (diffusion 
limited);  
pxrblk 2  = 0 min
-1 52  
VL2_PXR
_deg 
PXRproteinLigand2 degradation:  
)(2_2 tLigandPXRptoteink pxrl   [nM/min] 
pxrlk _2  = 0 min
-1 47 
VCYPmR
NA_synt_P
XR_L2 
CYPmRNA synthesis on active PXRproteinLigand2CYPgene:  
)(2__ tCYPgeneLigandPXRproteink bcypsynt   [nM/min] 
* bcypsyntk __ = 0min
-1 
VCYPmR
NA_PXR_
L2_binding 
PXRproteinLigand2 binding CYPgene: 
)()(2__ tCYPgenetLigandPXRproteink fcypbind   
)(2__ tCYPgeneLigandPXRproteink bcypbind   [nM/min] 
fcypbindk __  = 0 nM
-
1min-1 (diffusion 
limited);   
* bcypbindk __  = 0 min
-
1  
Vcort_distr
ibution 
Cortisol through the blood 
)(tCortOUTk ondistributi    [nM/min] 
ondistributik  = 1000 
min-1 
Vcort_CB
G 
Transport of cortisol through cellular membrane: 
)(1_ tCortOUTkcortCBG  )(_2_ tCortOUTCBGkcortCBG   [nM/min]
1_cortCBGk  = 60 nM
-
1min-1 (diffusion 
limited);   
2_cortCBGk  = 270 
min-1  
Vcort_albu
min 
)(1_ tCortOUTkcortALB  )(_2_ tCortOUTAlbkcortALB   1_cortALBk  = 60 nM-
1min-1 (diffusion 
limited);   
2_cortALBk  = 900000 
min-1  
 
Supplementary Table S2: Balance Equations for cortisol (L1) model  
Balance equations 
dCort(t)/dt -v15+v16 –v17+v18-v19+v42+ VcortisolTransport [nM/min] 
dCortAdded(t)/dt - Vcort_distribution[nM/min] 
dCortOUT(t)/dt  Vcort_distribution -Vcort_albumin - Vcort_CBG - VcortisolTransport 
[nM/min] 
dCBG_CortOUT(t)/dt Vcort_CBG[nM/min] 
dAlb_CortOUT(t)/dt Vcort_albumin [nM/min] 
dCBG(t)/dt -Vcort_CBG[nM/min] 
dAlb(t)/dt -Vcort_albumin [nM/min] 
dCortisone(t)/dt 0 (considered an infinite reservoir) 
dCYPgene(t)/dt -v20-v33 [nM/min] 
dCYPprotein(t)/dt +v3-v4 [nM/min] 
dCYPmRNA(t) /dt +v1-v2 +v21+v34+VCYPmRNA_PXR_L2_binding [nM/min] 
dPXRproteinCortCYPgene(t) /dt +v20 [nM/min] 
dPXRproteinLigand2CYPgene(t) /dt + VCYPmRNA_PXR_L2_binding- VCYPmRNA_synt_PXR_L2 [nM/min] 
dPXRproteinDEXCYPgene(t) /dt +v33 [nM/min] 
dDEX(t)/dt -v28+v29 –v30+v31-v32+v41 [nM/min] 
dLigand2(t)/dt - VL2_PXR_binding+ VL2_PXR_deg [nM/min] 
dDEXdeg(t)/dt +v32 [nM/min] 
dDEXout(t)/dt -v41 [nM/min] 
dGRgene(t)/dt -v24 -v37 [nM/min] 
dGRprotein(t)/dt +v11-v12-v15-v12-v28 [nM/min] 
dGRmRNA(t)/dt +v9-v10+v25+v38 [nM/min] 
dGRproteinCortGRgene(t)/dt +v24 [nM/min] 
dGRproteinDEXGRgene(t)/dt +v37 [nM/min] 
dGRproteinCort(t)/dt +v15-v16-v22-v24-v26 [nM/min] 
dGRproteinDEX(t)/dt +v28-v29-v35-v37-v39 [nM/min] 
dPXRgene(t)/dt -v35 –v22 [nM/min] 
dPXRprotein(t)/dt +v7-v8-v17-v30 [nM/min] 
dPXRmRNA(t)/dt +v5-v6+v23+v36 [nM/min] 
dGRproteinCortPXRgene(t)/dt +v22 [nM/min] 
dGRproteinDEXPXRgene(t)/dt +v35 [nM/min] 
dPXRproteinCort(t)/dt +v17-v18-v20 [nM/min] 
dPXRproteinLigand2(t)/dt +VL2_PXR_binding-VL2_PXR_deg-VCYPmRNA_PXR_L2_binding 
[nM/min] 
dPXRproteinDEX(t)/dt +v30-v31-v33 [nM/min] 
dTATgene(t)/dt -v26-v39 [nM/min] 
dTATmRNA(t)/dt +v13-v14+v27+v40 [nM/min] 
dGRproteinCortTATgene(t)/dt +v26 [nM/min] 
dGRproteinDEXTATgene(t)/dt +v39 [nM/min] 
dTATprotein(t)/dt +v43-v44 [nM/min] 
 
Supplementary Table S3: Conserved Moieties for cortisol (L1) model  
Conserved Moieties 
GRgenetotal GRgene(t) + GRproteinCortGRgene(t) + 
GRproteinDEXGRgene(t)  
****0.83 [nM] 
PXRgenetotal PXRgene(t) + GRproteinCortPXRgene(t) + 
GRproteinDEXPXRgene(t) 
****0.83 [nM] 
CYPgenetotal CYPgene(t) + PXRproteinCortCYPgene(t) + 
PXRproteinLigand2CYPgene(t)+ 
PXRproteinDEXCYPgene(t) 
****0.83 [nM] 
DEXtotal DEX(t) + DEXdeg(t) + DEXout(t) + 1000 [nM] 
GRproteinDEXGRgene(t) + GRproteinDEX(t) + 
GRproteinDEXPXRgene(t) + PXRproteinDEX(t) + 
GRproteinDEXTATgene(t)  + 
PXRproteinDEXCYPgene(t) 
 
 
Supplementary Table S4: Initial Conditions for cortisol (L1) model  
Initial conditions 
Cort(0) 1.14 [nM] 
Cortisone(0) 23 [nM] 
CortOUT(0) 0[nM] 
CortAdded(0) 0[nM] at t=0 for the initial state, then ~130 [nM] added 
into the blood as an exposure of cortisol. 
CBG_CortOUT(0) 0[nM] 
Alb_CortOUT(0) 0[nM] 
CBG(0) 550[nM] 
Alb(0) 60000[nM] 
Ligand2(0) 0[nM] 
CYPgene(0) 0.82976 [nM] 
CYPprotein(0) 104 [nM] 
CYPmRNA(0) 75e-3 [nM]  
94x levels of GR mRNA. Experimentally derived and 
consistent with 58,59 
PXRproteinCortCYPgene(0) 0.00024 [nM] 
PXRproteinLigand2CYPgene(0) 0 [nM] 
PXRproteinDEXCYPgene(0) 0 [nM] 
DEX(0) 0 [nM] 
DEXdeg(0) 0 [nM] 
DEXout(0) 1000 [nM] 
GRgene(0) 0.5 [nM] 
GRprotein(0) GRtotal=80.0 nM 
=GR (47.24) +GRprotCort(32.36) + GRprotCortGRgene 
(0.33) + GRproteinCortTATgene(0.02) + 
GRproteinCortPXRgene(0.05) 
60,61 
GRmRNA/dt 0.0008 [nM]  
Experimentally derived and consistent with 58,62 
GRproteinCortGRgene(0) 0.33 [nM] 
GRproteinDEXGRgene(0) 0 [nM] 
GRproteinCort(0) 32.36 [nM] 
GRproteinDEX(0) 0 [nM] 
PXRgene(0) 0.78 [nM] 
PXRprotein(0) *****99.9 [nM]  
PXRmRNA(0) 0.007 [nM]  
9x levels of GR mRNA. Experimentally derived and 
consistent with 58,59 
GRproteinCortPXRgene(0) 0.05 [nM] 
GRproteinDEXPXRgene(0) 0 [nM] 
PXRproteinCort(0) 0.01 [nM] 
PXRproteinLigand2(0) 0 [nM] 
PXRproteinDEX(0) 0 [nM] 
TATgene(0) 0.81 [nM] 
TATmRNA(0) 0.4[nM] 
Experimentally derived and consistent with 
http://www.genecards.org/ 
TATprotein(0) 0.462028 [nM] 
GRproteinCortTATgene(0) 0.02 [nM] 
GRproteinDEXTATgene(0) 0 [nM] 
 
Supplementary Table S5: Model Parameters for cortisol (L1) and second ligand (L2) model 
Reactions Parameters 
v1 CYPmRNA synthesis:  
)(1 tCYPgenek   [nM/min] 
* 1k = 0.00321 min
-1 
v2 CYPmRNA degradation:  
)(2 tCYPmRNAk   [nM/min] 
2k = 0.04 min
-1  
41,42 
v3 CYPprotein synthesis:  
)(3 tCYPmRNAk   [nM/min] 
3k = 2.5 min
-1 41 
v4 CYPprotein degradation:  
)(4 tCYPptoteink   [nM/min] 
4k = 0.0005 min
-1
43,44 
v5 PXRmRNA synthesis on inactive PXRgene:  
)(5 tPXRgenek   [nM/min] 
* 5k = 5.52e-05 min
-
1 
v6 PXRmRNA degradation:  
)(6 tPXRmRNAk   [nM/min] 
** 6k = 0.006 min
-1 
45 
v7 PXRprotein synthesis:  
)(7 tPXRmRNAk   [nM/min] 
7k = 10 min
-1 46 
v8 PXRprotein degradation:  
)(8 tPXRptoteink   [nM/min] 
8k = 0.003 min
-1 47 
v9 GRmRNA synthesis on inactive GRgene:  
)(9 tGRgenek   [nM/min] 
* 9k  = 3.2e-06 min
-1 
v10 GRmRNA degradation:  
)(10 tGRmRNAk   [nM/min] 
** 10k  = 0.003 min
-1
45 
v11 GRprotein synthesis:  
)(11 tGRmRNAk   [nM/min] 
11k = 19.98 min
-1 48 
v12 GRprotein degradation:  
)(12 tGRptoteink   [nM/min] 
12k  = 0.001 min
-1 
48,49 
v13 TATmRNA synthesis on inactive TATgene:  
)(13 tTATgenek   [nM/min] 
* 13k  = 0.000855 
min-1 
v14 TATmRNA degradation:  
)(14 tTATmRNAk   [nM/min] 
14k  = 0.064 min
-1 50 
v15 Cortisol binding GRprotein: 
)()( 1515 tortGRproteinCkGRproteintCortk bf   [nM/min] 
fk15  = 60 nM
-1min-1 
(diffusion limited); 
bk15  = 600 min
-1 
(Kd = 10 nM 51) 
v16 GRproteinCort degradation:  
)(16 tortGRptoteinCk   [nmoles/min] 
16k  = 0.001 min
-1
48,49 
v17 Cortisol binding PXRprotein: 
)()( 1717 tCortPXRproteinkPXRproteintCortk bf   [nM/min] 
fk17  = 60 nM
-1min-1 
(diffusion limited);  
bk17  = 600000 min
-1 
52  
v18 PXRproteinCort degradation:  
)(18 tCortPXRptoteink   [nM/min] 
18k  = 0.0015 min
-1
47 
v19 Cort degradation:  
2
)(2)(1
)(
MLMC
MC
mC
K
tL
K
tCort
K
tCortV
CYPptotein


  [nM/min] 
mCV  = 10 min
-1
(kcat= mCV / 1200(nM 
max CYP protein 
conc in cell) nM = 
0.083);  
MCK =15000 nM 
Since L2=0, 
Competition 
between cortisol 
and L2 for CYP is 
neglected 53,54 
v20 PXRpoteinCortisol binding CYPgene: fk20  = 60 nM
-1min-1 
)()(20 tCYPgenetCortPXRproteink f   
)(20 teCortCYPgenPXRproteink b   [nM/min] 
(diffusion limited);   
* bk20  = 1 min
-1  
v21 CYPmRNA synthesis on active PXRproteinCortCYPgene:  
)(21 teCortCYPgenPXRproteink   [nM/min] 
* bk21 = 0.05 min
-1 
v22 GRpoteinCortisol binding PXRgene: 
)()(22 tPXRgenetortGRproteinCk f   
)(22 tortPXRgeneGRproteinCk b   [nM/min] 
fk22  = 60 nM
-1min-1 
(diffusion limited);   
* bk22  = 200 min
-1 
v23 PXRmRNA synthesis on active GRproteinCortPXRgene:  
)(23 tortPXRgeneGRproteinCk   [nM/min] 
* 23k = 0.00011 min
-
1 
v24 GRpoteinCortisol binding GRgene: 
)()(24 tGRgenetortGRproteinCk f   
)(24 tortGRgeneGRproteinCk b   [nM/min] 
fk24  = 60 nM
-1min-1 
(diffusion limited);   
* bk24  = 60 min
-1 
v25 GRmRNA synthesis on active GRproteinCortGRgene:  
)(25 tortGRgeneGRproteinCk   [nM/min] 
* 25k = 1.2e-06 min
-1
v26 GRpoteinCortisol binding TATgene: 
)()(26 tTATgenetortGRproteinCk f   
)(26 tortTATgeneGRproteinCk b   [nM/min] 
fk26  = 60 nM
-1min-1 
(diffusion limited);   
* bk26  = 300 min
-1 
v27 TATmRNA synthesis on active GRproteinCortTATgene:  
)(27 tortTATgeneGRproteinCk   [nM/min] 
* 27k = 0.005 min
-1  
v28 DEX binding GRprotein: 
)()( 2828 tEXGRproteinDkGRproteintDEXk bf   [nM/min] 
fk28  = 60 nM
-1min-1 
(diffusion limited);  
bk28  = 60 min
-1  
(calculated from Kd 
that is in the order 
of magnitude of 1 
nM 55) 
v29 GRproteinDEX degradation:  
)(29 tEXGRptoteinDk   [nmoles/min] 
29k  = 0.001 min
-1 
48,49 
v30 DEX binding PXRprotein: 
)()( 3030 tDEXPXRproteinkPXRproteintDEXk bf   [nM/min] 
fk30  = 60 nM
-1min-1 
(diffusion limited);;  
bk30  = 60000 min
-1 
(calculated from Kd 
that is in the order 
of magnitude of 
1000 nM 56) 
v31 PXRproteinDEX degradation:  
)(31 tDEXPXRptoteink   [nmoles/min] 
** 31k  = 0.0015 
min-147 
v32 DEX degradation:  
2:
)(2)()(1
)(
MMCMDEX
MDEX
mDEX
K
tL
K
tCort
K
tDEX
K
tDEXV
CYPptotein


  [nM/min] 
mDEXV  = 5.1 min
-1; 
((kcat= mCV / 1200 
(max CYP protein 
conc in cell) nM = 
0.00425);) 
MDEXK =23000 nM 
57  
v33 PXRpoteinDEX binding CYPgene: 
)()(33 tCYPgenetDEXPXRproteink f   
)(33 tDEXCYPgenePXRproteink b   [nM/min] 
fk33  = 60 nM
-1min-1 
(diffusion limited);   
* bk33  = 1 min
-1 
v34 CYPmRNA synthesis on active PXRproteinDEXCYPgene:  
)(34 tDEXCYPgenePXRproteink   [nM/min] 
* 34k = 0.05 min
-1 
v35 GRpoteinDEX binding PXRgene: 
)()(35 tPXRgenetEXGRproteinDk f   
)(35 tEXPXRgeneGRproteinDk b   [nM/min] 
fk35  = 60 nM
-1min-1 
(diffusion limited);   
* bk35  = 200 min
-1 
v36 PXRmRNA synthesis on active GRproteinDEXPXRgene:  
)(36 tEXPXRgeneGRproteinDk   [nM/min] 
* 36k = 0.00011 min
-
1 
v37 GRpoteinDEX binding GRgene: 
)()(37 tGRgenetEXGRproteinDk f   
)(37 tEXGRgeneGRproteinDk b   [nM/min] 
fk37  = 60 nM
-1min-1 
(diffusion limited);   
* bk37  = 60 min
-1 
v38 GRmRNA synthesis on active GRproteinDEXGRgene:  
)(38 tEXGRgeneGRproteinDk   [nM/min] 
* 38k = 1.2e-06 min
-
1 
v39 GRpoteinDEX binding TATgene: 
)()(39 tTATgenetEXGRproteinDk f   
)(39 tEXTATgeneGRproteinDk b   [nM/min] 
fk39  = 60 nM
-1min-1 
(diffusion limited);   
* bk39  = 300 min
-1 
v40 TATmRNA synthesis on active GRproteinDEXTATgene:  
)(40 tEXTATgeneGRproteinDk   [nM/min] 
* 40k = 0.005 min
-1 
v41 DEX transport through cellular membrane: 
)(41 tDEXoutk f   )(41 tDEXink b   [nM/min] 
fk41  = 100 min
-1;  
bk41  = 100 min
-1  
(taken at high value 
not to limit DEX 
uptake)  
v42 Endogenous cortisol synthesis: fk42  = 0.016 min
-1;  
)(42 tCortisonek f   )(42 tCortk b   [nM/min] bk42  = 0.016  min-1 
(fitted to have 
realistic cortisol 
concentration) 
V43 TATprotein synthesis:  
)(43 tTATmRNAk   [nM/min] 
* 43k = 0.5 min
-1 
v44 
 
 
TATprotein degradation:  
)(44 tTATptoteink   [nM/min] 
44k = 0.012 min
-1 50 
VcortisolT
ransport 
Transport of cortisol through cellular membrane: 
)(tCortOUTkctf   )(tCortkctb   [nM/min] 
ctfk  = 1000 min
-1;  
ctbk  = 1000 min
-1  
VL2_PXR
_binding 
Ligand2 binding PXRprotein: 
)(2)(2 22 tLigandPXRproteinkPXRproteintLk pxrblpxrfl   
[nM/min] 
pxrfk12  = 60 nM
-
1min-1 (diffusion 
limited);  
pxrblk 2  = 600000 
min-1 52  
VL2_PXR
_deg 
PXRproteinLigand2 degradation:  
)(2_2 tLigandPXRptoteink pxrl   [nM/min] 
pxrlk _2  = 0.0015 
min-1 47 
VCYPmR
NA_synt_P
XR_L2 
CYPmRNA synthesis on active PXRproteinLigand2CYPgene:  
)(2__ tCYPgeneLigandPXRproteink bcypsynt   [nM/min] 
* bcypsyntk __ = 0.05 
min-1 
VCYPmR
NA_PXR_
L2_binding 
PXRproteinLigand2 binding CYPgene: 
)()(2__ tCYPgenetLigandPXRproteink fcypbind   
)(2__ tCYPgeneLigandPXRproteink bcypbind   [nM/min] 
fcypbindk __  = 60 nM
-
1min-1 (diffusion 
limited);   
* bcypbindk __  = 1 min
-
1  
Vcort_distr
ibution 
Cortisol through the blood 
)(tCortOUTk ondistributi    [nM/min] 
ondistributik  = 1000 
min-1 
Vcort_CB
G 
Transport of cortisol through cellular membrane: 
)(1_ tCortOUTkcortCBG  )(_2_ tCortOUTCBGkcortCBG   [nM/min]
1_cortCBGk  = 60 nM
-
1min-1 (diffusion 
limited);   
2_cortCBGk  = 270 
min-1  
Vcort_albu
min 
)(1_ tCortOUTkcortALB  )(_2_ tCortOUTAlbkcortALB   1_cortALBk  = 60 nM-
1min-1 (diffusion 
limited);   
2_cortALBk  = 900000 
min-1  
 
Supplementary Table S6: Balance Equations for cortisol (L1) and second ligand (L2) model 
Balance equations 
dCort(t)/dt -v15+v16 –v17+v18-v19+v42+ VcortisolTransport [nM/min] 
dCortAdded(t)/dt - Vcort_distribution[nM/min] 
dCortOUT(t)/dt  Vcort_distribution -Vcort_albumin - Vcort_CBG - VcortisolTransport 
[nM/min] 
dCBG_CortOUT(t)/dt Vcort_CBG[nM/min] 
dAlb_CortOUT(t)/dt Vcort_albumin [nM/min] 
dCBG(t)/dt -Vcort_CBG[nM/min] 
dAlb(t)/dt -Vcort_albumin [nM/min] 
dCortisone(t)/dt 0 (considered an infinite reservoir) 
dCYPgene(t)/dt -v20-v33 [nM/min] 
dCYPprotein(t)/dt +v3-v4 [nM/min] 
dCYPmRNA(t) /dt +v1-v2 +v21+v34+VCYPmRNA_PXR_L2_binding [nM/min] 
dPXRproteinCortCYPgene(t) /dt +v20 [nM/min] 
dPXRproteinLigand2CYPgene(t) /dt + VCYPmRNA_PXR_L2_binding- VCYPmRNA_synt_PXR_L2 [nM/min] 
dPXRproteinDEXCYPgene(t) /dt +v33 [nM/min] 
dDEX(t)/dt -v28+v29 –v30+v31-v32+v41 [nM/min] 
dLigand2(t)/dt - VL2_PXR_binding+ VL2_PXR_deg [nM/min] 
dDEXdeg(t)/dt +v32 [nM/min] 
dDEXout(t)/dt -v41 [nM/min] 
dGRgene(t)/dt -v24 -v37 [nM/min] 
dGRprotein(t)/dt +v11-v12-v15-v12-v28 [nM/min] 
dGRmRNA(t)/dt +v9-v10+v25+v38 [nM/min] 
dGRproteinCortGRgene(t)/dt +v24 [nM/min] 
dGRproteinDEXGRgene(t)/dt +v37 [nM/min] 
dGRproteinCort(t)/dt +v15-v16-v22-v24-v26 [nM/min] 
dGRproteinDEX(t)/dt +v28-v29-v35-v37-v39 [nM/min] 
dPXRgene(t)/dt -v35 –v22 [nM/min] 
dPXRprotein(t)/dt +v7-v8-v17-v30 [nM/min] 
dPXRmRNA(t)/dt +v5-v6+v23+v36 [nM/min] 
dGRproteinCortPXRgene(t)/dt +v22 [nM/min] 
dGRproteinDEXPXRgene(t)/dt +v35 [nM/min] 
dPXRproteinCort(t)/dt +v17-v18-v20 [nM/min] 
dPXRproteinLigand2(t)/dt +VL2_PXR_binding-VL2_PXR_deg-VCYPmRNA_PXR_L2_binding 
[nM/min] 
dPXRproteinDEX(t)/dt +v30-v31-v33 [nM/min] 
dTATgene(t)/dt -v26-v39 [nM/min] 
dTATmRNA(t)/dt +v13-v14+v27+v40 [nM/min] 
dGRproteinCortTATgene(t)/dt +v26 [nM/min] 
dGRproteinDEXTATgene(t)/dt +v39 [nM/min] 
dTATprotein(t)/dt +v43-v44 [nM/min] 
 
Supplementary Table S7: Conserved Moieties for cortisol (L1) and second ligand (L2) model 
Conserved Moieties 
GRgenetotal GRgene(t) + GRproteinCortGRgene(t) + 
GRproteinDEXGRgene(t)  
****0.83 [nM] 
PXRgenetotal PXRgene(t) + GRproteinCortPXRgene(t) + 
GRproteinDEXPXRgene(t) 
****0.83 [nM] 
CYPgenetotal CYPgene(t) + PXRproteinCortCYPgene(t) + 
PXRproteinLigand2CYPgene(t)+ 
PXRproteinDEXCYPgene(t) 
****0.83 [nM] 
DEXtotal DEX(t) + DEXdeg(t) + DEXout(t) + 
GRproteinDEXGRgene(t) + GRproteinDEX(t) + 
GRproteinDEXPXRgene(t) + PXRproteinDEX(t) + 
GRproteinDEXTATgene(t)  + 
PXRproteinDEXCYPgene(t) 
1000 [nM] 
 
Supplementary Table S8: Initial Conditions for cortisol (L1) and second ligand (L2) model 
Initial conditions 
Cort(0) 1.14 [nM] 
Cortisone(0) 23 [nM] 
CortOUT(0) 0[nM] 
CortAdded(0) 0[nM] at t=0 for the initial state, then ~130 [nM] added 
into the blood as an exposure of cortisol. 
CBG_CortOUT(0) 0[nM] 
Alb_CortOUT(0) 0[nM] 
CBG(0) 550[nM] 
Alb(0) 60000[nM] 
Ligand2(0) 100[nM] 
CYPgene(0) 0.82976 [nM] 
CYPprotein(0) 104 [nM] 
CYPmRNA(0) 75e-3 [nM]  
94x levels of GR mRNA. Experimentally derived and 
consistent with 58,59 
PXRproteinCortCYPgene(0) 0.00024 [nM] 
PXRproteinLigand2CYPgene(0) 0 [nM] 
PXRproteinDEXCYPgene(0) 0 [nM] 
DEX(0) 0 [nM] 
DEXdeg(0) 0 [nM] 
DEXout(0) 1000 [nM] 
GRgene(0) 0.5 [nM] 
GRprotein(0) GRtotal=80.0 nM 
=GR (47.24) +GRprotCort(32.36) + GRprotCortGRgene 
(0.33) + GRproteinCortTATgene(0.02) + 
GRproteinCortPXRgene(0.05) 
60,61 
GRmRNA/dt 0.0008 [nM]  
Experimentally derived and consistent with 58,62 
GRproteinCortGRgene(0) 0.33 [nM] 
GRproteinDEXGRgene(0) 0 [nM] 
GRproteinCort(0) 32.36 [nM] 
GRproteinDEX(0) 0 [nM] 
PXRgene(0) 0.78 [nM] 
PXRprotein(0) *****99.9 [nM]  
PXRmRNA(0) 0.007 [nM]  
9x level of GR mRNA. Experimentally derived and 
consistent with 58,59 
GRproteinCortPXRgene(0) 0.05 [nM] 
GRproteinDEXPXRgene(0) 0 [nM] 
PXRproteinCort(0) 0.01 [nM] 
PXRproteinLigand2(0) 0 [nM] 
PXRproteinDEX(0) 0 [nM] 
TATgene(0) 0.81 [nM] 
TATmRNA(0) 0.4[nM] 
Experimentally derived and consistent with 
http://www.genecards.org/ 
TATprotein(0) 0.462028 [nM] 
GRproteinCortTATgene(0) 0.02 [nM] 
GRproteinDEXTATgene(0) 0 [nM] 
  
*mRNA and protein synthesis rates are fitted according to the experimental data obtained. 
**mRNA and protein degradation are fitted to concur with 63 
***Kd of binding of liganded NRs to REs is fitted in the realistic order of magnitude 64 
**** Taken in the realistic order of magnitude that is calculated from (~1.710-12 nmoles of REs (1,000 
molecules) per cell (de Kloet et al, 2000), consequently per volume of nucleus. Volume of nucleus  is 
~0.4510-12  L 61) 
*****Taken in the realistic order of magnitude that is calculated from (NR total=NR + NRDEX 
+NRCortisol is 1.710-9 nmoles (100,000 molecules) per cell 60,65; volume of cell is ~210-12  L 61 
Supplementary Table S9: Sensitivity analysis of main conclusions for Figure 2
 
  
Supplementary Table S10: Sensitivity analysis of main conclusions for Figure 3
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